side effects of glp 1 tirzepatide Managing GLP-1 Receptor Agonists – Transformation Weight Control Retatrutide vs Tirzepatide (2026): Differences
Description
Her relatively milder course underscores that, while not all patients develop severe or ischemic obstruction, the risk spectrum ranges from partial to complete obstruction depending on individual susceptibility
PMID: 32162607 Pajuelo D, et al
From a pharmacological perspective, these medications can generally be stopped abruptly without causing acute adverse effects or rebound phenomena
Protein and fibre become non-negotiable
Participants maintained a reduced dosing frequency for an average of 36 weeks
doi:10.1016/j.expneurol.2013.11.001 182
